Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes
American Journal of Kidney Diseases · 2026-06-01
Comparative Effectiveness of Individual Sodium Glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 2 Diabetes With Moderate Cardiovascular Risk: Emulation of a Target Trial
Journal of the American Heart Association · 2026-05-14
Comparative effectiveness of sulfonylureas on kidney outcomes in adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation
BMJ Open Diabetes Research & Care · 2026-05-01
Cardiovascular Effects of Alogliptin, Linagliptin, Saxagliptin, and Sitagliptin: A Target Trial Emulation of a Comparative Effectiveness Study
Endocrine Practice · 2026-04-01
Supplementary Methods from Breast Cancer Risk Modification in Women with Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, <i>ATM</i>, <i>CHEK2</i>, and <i>PALB2</i>
2026-03-16
Supplementary Table 1 from Breast Cancer Risk Modification in Women with Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, <i>ATM</i>, <i>CHEK2</i>, and <i>PALB2</i>
2026-03-16
Lower Extremity Complications in Adults With Type 2 Diabetes Treated With Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas: An Emulated Target Trial
Endocrine Practice · 2026-02-02 · 2 citations
Comparative safety of sulfonylurea therapies on cardiovascular and severe hypoglycemia outcomes among adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation
BMJ Open Diabetes Research & Care · 2026-01-01 · 1 citations
Supplementary Materials, Figure S1-S4, Table S1-S9 from Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C
2025-11-24
Pathogenic Variants, Family History, and Cumulative Risk of Breast Cancer in US Women
JAMA Oncology · 2025-10-09 · 6 citations
Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial
Diabetes Research and Clinical Practice · 2025-09-22 · 6 citations
Comparative Risk of Adverse Pancreatic Events With GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas Among Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk
Endocrine Practice · 2025-09-12
Abstract 013: Comparative Improvement in Cardiovascular Outcomes of Individual SGLT2i Drugs in Individuals with Type 2 Diabetes at Moderate Cardiovascular Risk
Hypertension · 2025-09-01
Using telematics data to evaluate safety policies: a case study of Chicago’s red-light camera programme
Injury Prevention · 2025-08-27
Development of an alcohol biosensor non-wear algorithm: laboratory-based machine learning and field-based deployment
Scientific Reports · 2025-08-25
Risk of Sight-Threatening Diabetic Retinopathy with Glucagon-Like Peptide-1 Receptor Agonist Use in Routine Clinical Practice
Ophthalmology Retina · 2025-08-06 · 5 citations
Heterogeneity of Cardiovascular Effects of Second‐Line Glucose‐Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular Risk
Journal of the American Heart Association · 2025-07-17 · 2 citations
780-P: Comparative Risk of Adverse Pancreatic Events with Second-Line Glucose-Lowering Therapies in Adults with Type 2 Diabetes at Moderate Cardiovascular Disease Risk
Diabetes · 2025-06-13
779-P: Cardiovascular Outcomes Associated with Dulaglutide, Exenatide, Liraglutide, and Semaglutide in Adults with Type 2 Diabetes at Moderate Cardiovascular Risk
Diabetes · 2025-06-13
308-OR: Risk of New Cancer Diagnoses with GLP-1 Receptor Agonist, SGLT2 Inhibitor, DPP-4 Inhibitor, and Sulfonylurea Use in Type 2 Diabetes
Diabetes · 2025-06-13